Healthcare News 6

• "Ho Hum" to Abbott's Free Style Blood Glucose Meter
• 7 vs 3? Threat to Medtronics??
• A bad portent for patents
• A Complete Revolution Takes You Back to Where You Started
• A Monitoring Revolution
• A new revenue stream or more Medicare frustration?
• A novel approach
• A potential signifcant downside.
• A step in the right direction.
• Abaxapin is a promising oral anticoagulant, but has to seriously compete with Dabigratan
• Abotts new psoriasis drug
• ABT
• Acanthamoeba keratitis
• Accuray's cyberknife therapy gets strong validation
• ACE Inhibitors may affect the brain in as yet unknown ways
• Actos (Takeda Pharm) unfairly lumped in with Avandia (Glaxo; GSK)
• AIDS and Heart Disease
• Ajudication in healthcare matters should be fair, but not necessarily a way to make a killing
• ALKS 27 in COPD
• Allergies and Uveitis: Is there a Connection?
• Already here....
• Already in heavy use
• Altace plus hydrochlorothiazide – ho hum or tip of the iceberg?
• Altace: is more better?
• Ambien Goes Generic: What will the Market Look Like?
• Ambien(R): Caraco Pharmaceutical Laboratories Ltd. to Rise, Sanofi –Aventis to fall a some
• AMD Treatments
• Amerigroup - Another Medicaid HMO with an Increasing Medical Loss Ratio
• AMO Solution Is Not Contaminated- But it is not killing off Amoeba's
• Amoxicillin PULSYS approval
• AMP will exclude PBM Rebates
• An added benefit
• An also-ran in a crowded market
• An Appropriate Warning about Vitamins/Supplements and Prostate Cancer
• An easy sell
• An Insurance Company Facilitates Healthcare for a Change
• An ounce of prevention IS worth a pound of cure
• anemia and cancer
• Another "me too" drug with no great advantage
• Another Advicor?
• Another headache for Amgen
• Another misstep
• Another potential therapy for IBS?
• Another Spiriva?
• Another success story for Gleevec
• ANTIDEPRESSION market whats new, what's not: generics
• Are Current Health IT Systems Up to the Task of Permitting Quality Performance Reporting?
• Are Mothers Still the Deciders in Health Care
• Are the Shopping Malls Next?
• Arformoterol (Sepracor) niche
• Arsenicals for cancer Treatment: Will the sucess in APL be replicated for Liver cancer??
• ASCO blockbuster?? The Good, the Bad and Reality
• Asian collaboration is logical for treatment of Gastric cancer
• Aspire Implant May Lead to Re-Education of Some Sleepy Patients.
• Aspire Implant May Take A Bite Out of Sleep Med Market
• Asthma prevention
• AstraZeneca (AZN) hits jackpot
• AstraZeneca's Tries to Hedge its Bets with Serqouel XR
• Attack on the big 3
• Avandia is safe and effective, when used correctly
• Avandia report raises more questions than answers
• Avanir's New Clozaril Formulation (12.5mg in bottles!) -- A Big Yawn?
• Avastin for renal cell carcinoma: Role in combination chemotherapy
• AZ's SMART Symbicort for Asthma
• Back to the future
• Bad news for Avandia and Glaxo
• Ban DTC advertising
• Bariatric surgery-- when all else fails in diabetic patients
• Bariatric Surgery: Too much, Too early.
• be careful what you ask for
• Be skeptical of RFID hype
• Benefits of Nebulized Epineprine Short Lived
• Better control vs. more side effects.
• Beware of Generic Generalizations - Some Patients are DNS
• Biological generic drugs the expensive alternative
• Bleeding will be key
• Bristol Myer Squibb’s Abilify as an Augmentation Strategy for Depression
• Brokering a deal for HIV drugs is a big win
• Calcitonin for OA
• Can only be a help.
• Cause and effect between vitamin use and prostate cancer not established
• Cediranib for Glioblastoma: Promising results need confirmation in alrger trial
• Centers for Medicare & Medicaid Services (CMS) proposed to create “mega” fraud contractor - Will this impact AHG, LNCR, RESP, IVC, RMD and AHP?
• Ceragenix Epiceram product phase 4 results positive
• Cervarix gets the nod in Australia for a wider age range than Gardasil
• Cervarix is an effective vaccine agiast HPV , but has to catch up with Gardasil
• Cervarix is not a treatment for cancer; compare to Gardasil
• Cethromycin - a promising new ketolide
• Challenges ahead for Provider and Clinic Reimbursement
• Cipralex (Lexapro) Trumps Duloxetine - or Does it?
• Clinical Trial Missteps are Difficult to Retrace
• Clretazine is not very effective for AML , but amy be so for barin tumors.
• CMS excuses or concerns for not reimbursing care
• Combination Rx for Asthma
• Combo pill will have difficulty with availability of generic Lotrel from Teva
• Compare it to Coreg and Toprol XL
• Compare it to Lotrel
• Comparison of XYZAL to Hismanal (Astemizole)
• Concern of Erythropoetin is Warranted
• Confusing Cause and AFFECT
• Cortisol and Psychiatric Disorders
• Cosmeceuticals are great for rich uninformed clients
• Couldn't agree more
• Cryoablation has advantages and disadvantages
• Cryoablation offers significant hope for low grade and stage cancer patients
• Curb your enthusiasm- a cautionary tale about new diabetes drugs.
• DEA Speaks and Vyvanse Poises for Market Launch
• Decreasing steroid use in stable asthma
• Define Blockbuster?
• Democrats Like Health IT Too
• Dendreon Delay Reveals Pitfuls of Drug Development/Accessibility
• Depression is Depression Independent of Casuality
• DexCom
• Diabetes drugs and heart disease
• Diet rich in Fish Oils (Omega 3 Fatty Acids) significantly reduces of WET Age Related Macular Degeneration.
• Discount Plastic Surgery - You Generally Get What You Pay For
• Discount prices lead to Shortcut Surgery
• Disease management for Medicare Advantage
• Doctors and Investment Bankers are Only Human
• Doctors should consider patient out of pocket costs
• Does Phacoemulsification and IOL Implantation prevent Glaucoma?
• Don't jump on board too quickly....
• Dont't Hold Your Breath II
• Double- Edged
• Double-edged if were used properly
• Doubt will be enough
• Drinking Wine for all the Wrong Reasons
• Drug Safety Monitoring: A Changing Culture at the FDA?
• Drugs and Devices: Will New FDA Legislation on Safety Impact Sales?
• Dry Eye Syndrome - Novagali
• DTC Education (not Advertising) is the Key
• Dual action is the key
• Early diagnosis of TB
• Eat healthfully and you are less likely to get sick
• Efficacy?? Place in Therapy???
• EGS Antireflux Device
• Electronic Health Records: Smaller Providers NOT Ready For Prime Time
• Elephant gun
• Emerging Trends in Refractive Surgery: Wavefront, LASEK, Intralase, and Phakic IOLs.
• Employer/Employee Wellness promotes health and productivity
• Endoscopic Solution for GERD?
• EPO Safe When Used Within Guidelines Governing Use
• Erbitux and impact of EPIC proportions
• Erbitux like Avastin adds nothing to pancreatic cancer
• ESI throws Pfizer a bone
• Everything is relative.
• Evolution of Fluoroscopy: More Usage, Better Technology
• Evotec AG Scores a Technical Knockout in Sleep Arena...Here's Why
• Exelixis TKI's in a crowded market
• Exforge: teaching old dogs old tricks
• Exilexis targeted therapies may have promise in lung cancer and hematological malignancies , but face fierce competition
• FazaClo Announcement a Yawner
• FDA ban on Hydroquinones
• FDA concerns about Aranesp and other ESA's are Justified
• FDA Extends Antidepressant Black Box Warning to Young Adults
• FDA heavy handed "but legal" pounces upon PharmaFab
• FDA Hydroquinone ban may be premature
• FDA needs to appoint a new advisory panel
• Fight the cells that cause the damage
• First Proof of the Use of Novel Magnetic Remote Controlled System for VT management
• Follow the GINA guidelines
• For AstraZeneca (AZN) and Seroquel XR - TIMING is EVERYTHING
• For wounds, it is going to happen
• GE Brings Good Things to Life (and Health?)
• Gene expression analysis
• Generic Biologicals will have limited Utility.
• Generic Biologicals: Lobbyists, and Congress people.
• Generic biologics
• Generic Fexofenadine
• Generic yes -safe?
• Generics hit the mark and save you money
• Gleevec moves toward the adjuvant setting in GIST
• globus adds to an already comprehensive product line
• Go to market internal controls are required by MA plans
• Good idea with potential for abuse
• Good news if study can be duplicated
• Good news, but use Altabax judiciously
• Good Times Ahead for Generics and Mylan
• Google Is Entering into Personal Health Records (PHR) Arena; IT
• Google's (Nasdaq:GOOG) Mastery of the Personal Medical Record Will be HUGE
• Grape Expectations: Yes If Not No Because.
• Ground Floor?
• Health Courts may streamline the medical malpractice course
• Healthways - Telephonic Care Support and Adherence to Standards, but what about Outcomes?
• Here to stay
• High dose higher risk
• Holy Grail Revisited?
• Honey, no headache tonite!
• How Promising is Deep Brain Stimulation for Depression?
• How to sell generic cholesterol fighting drugs.
• HPV vaccines have a long way to go
• Humira in Crohns Disease
• I don't think this drug will be successful
• I had the idea first
• I told you so....
• Idiopathic Pulmonary Haemosiderosis
• If only there was no malpractice.
• If Real, I'm Interested But Not Overwhelmed YET....
• If Starbucks and McDonald's can do it why not doctors
• Imaging Cuts Hurt Rural Patients
• IMDS - CTML - Value without contrast agents?
• Immunotherapy of lung cancer
• Impact of Symbicort on the U.S. Asthma Market
• Impact on Betaseron sales of early-tyreatment indication
• Implications of Smith & Nephew acquistion of BlueSky Medical
• Importance of diagnostics
• Importation & Drug Safety (PDUFA) now linked
• Impropved pancreatic duct imaging in MR - small market for Secretin
• Improved compliance with better communication
• Increase Demand Dramatic for generics by patients to their prescribing physicians (primary care and cardiologists)
• Individualized Immunotherapy for NHL: Innovative and promising in setting of residual disease
• Infections and Asthma
• Infliximab in COPD
• Infliximab in PMR and GA
• Inhalable insulins are too difficult for most patients
• Inhaled insulin: A drug for a loyal few
• Insulin and weight loss
• Insurance and Banking services are blossoming in India.
• Interesting approach
• Intraocular Therapies: An Exciting Time in Ophthalmology.
• Invasive Devices for Depression Not Catching On
• iron and aging
• Is Bariatric surgery for type 2 diabetes mellitus an overly simplistic solution
• Is better than albuterol
• Is it the disease or the therapy
• Is Macular Edema from Retinal Vein Occlusions another indication for Lucentis (Genetech; DNA)?
• Is Seroquel XR the answer?
• IS stroke and recuurent MI not cardiovascular endpoints?
• Is the "Garbage in Garbage Out" Complaint about Health Data about to Change?
• Is there a role for Visudyne (verteporfin, Novartis) PDT in the Lucentis (ranibizumab, Genentech) era?
• Is Wyeth's Torisel Better Than Wyeth's Rapamune?
• It is all a game!
• It may be quite naive to choose your wine based on resveratrol content
• JCAHO gets in on Medical Tourism Trend
• Keeping it simple
• Kidney Transplant Outcomes may improve with Rapamycin based Immunosupression
• King Pharmaceuticals - plus points of Altace/hydorchlorothiazide combination
• Knowing what is wrong does not necessarily mean you will do anything about it
• LADIES "VIAGRA(r)" ON THE HORIZON
• Lantus and Levemir, Separating the Wheat From the Chaff
• Lapatinib (Tyverb or Tykerb) Is An Improvement
• Lapatinib may have issues to deal with?
• Laser liposuction - not worth the risk...just yet
• Laser liposuction - not worth the risk...just yet
• Length still more important
• Let's Not Jump to Conclusions.
• LIBIDO ELEVATOR CLINICAL TRIAL CRITERIA
• Little impact
• Long term benefits of population based disease management
• Long Term Efficacy and Toxicity of Viral Entry Inhibitors Still Speculative
• Long-acting Seroquel: Astra-Zeneca Continues to Zoom to the top
• Lovenox- the way to go
• Lower doses of Alentuzumab may have an impact in the treatment of Multiple Sclerosis.
• Lower prices in the future for non-sedating anti-histamines
• LX1031 for IBS
• Lybrel
• Lybrel to eliminate periods..at what patient cost share?
• Making life easier
• Making the patient life easier
• Managed Care Difficulties
• managed Medicare plans have no proven advantages
• Medical Director of Pediatric Emergecncy Medicine for the ABHN and Chief Medcial Officer of PIRRGA ( Insuarance company)
• Medical E-records are a great idea
• Medicare Advantage
• Medicare Advantage, Could Funding Cuts be on the Way?
• Medicare Hospital Mortality Report Will HIt Hospitals Where they Live (Literally)
• Medicare Payments to Health Plans, The Government will Begin Ratcheting them Down
• Medicare should not pay for unsafe care
• MEDICARE TRUST FUND to CONTINUE
• Medicare will not cover disk replacement
• Melafind
• Melafind Phase three implications
• Men Mandate Maintenance and Makeovers to Maintain Marketability
• Mifamurtide in metastatic osteosracoma : Current data is not convincing
• MLN0002 in IBD
• Moderation in All Things
• Modus product-?efficacy
• Mommy Makeovers are on the Move
• More Generics Needed
• More Problems with the Marketing of Medicare Health Plans
• More Than Even I Expected.....
• mTor inhibitors are going to be big
• mTOR: a "dirty" drug with great potential
• Naryx antibiotic for chronic sinusitis
• Nebido for LIbido
• Nebivolol – What’s New?
• Need for further study
• Need to Limit Access to Competitive Foods
• Needed science if it proves itself to work
• Nerve damage in IBD
• Nerve Damage in Patients with IBD: Implications for causality or just an association?
• Neutral Results will not boost use of Aranesp and other ESA's
• New Access to Medical Care
• New biomarkers for psychiatric disorders
• New Corneal Imaging Devices are giving more Infomation to Ophthalmologists.
• New Fetal Monitor - Expect use and abuse
• New Organiceuticals May Help Bring Back Beauty!
• New stress agent at hand
• New therapy for rare tumor
• Nexavar for Hepatic cancer: " Vitamin N " for solid Tumors???
• Nicotine Vaccine - Unintended Consequences?
• No benefit beyond formulations already on market
• No cause and effect shown yet
• Non-contrast perfusion imaging is a significant advantage for Siemens over their competitors
• Non-Invasive Screening of the Skin
• Northfield's "PolyHeme" Blood Substitute: Evidence of an MI Class Effect
• Northfield's PolyHeme Blood Substitute Drama: Next Act in Less Than 30 Days
• Not enough
• Not good for Avandia
• Not new information
• Not precious - but something about copper peptides
• Not surprising
• Not the same but at the end of the "movie" it will be the same
• Not unexpected
• not yet
• Nothing new
• Novaritis does it again
• Novartis' Reclast for Osteoporosis
• Novel treatment for “breakthrough” cancer pain
• Off with his head!
• One less safety concern?
• Only 900 patients yearly in the US? Is there more than meets the eye??
• Opening AIDS patents are the future for older drugs
• Oracle latest acquisition - Agile for BI and Identity Mgmt
• Oral Glucose Lowering Medications...a caution is required.
• Orencia in RA
• Overtreatment of patients with mild asthma
• P4P: Would doctors be more enthusiastic if they got paid more?
• Pain-free needlesticks
• Panzem for refractory Multiple Myeloma: Need more data!!
• Patient Selection
• Patients will opt for less expensive Amoxicillin
• Pay for Performance Not Moving Fast Enough (Except for the AMA)
• Paying the price for ego
• PBM Ethics: Generics, Yes; MDs, Pharma, Employers, No
• PCR analysis offers hope of pre-event detection of public health risks in food industry
• PCR analysis offers hope of pre-event detection of public health risks in food industry
• PCR analysis offers hope of pre-event detection of public health risks in food industry
• PCR detetction of Salmonella food contamination not yet ready for prime time.
• PCR Used to Detect Bad Meat
• PDL's Novion in Ulcerative Colitis
• Pediatrician View/Emergency Medicine View
• Pfizer realizes that PBMs are the power players
• Pfizer’s Axitinib may be an option when “all else fails” with metastatic thyroid
• Pfizer’s Lyrica: On Its way to An Approved Treatment for Fibromyalgia?
• Pfizer's win on appeal sets an IP precedent globally. Good news for making NEW drugs.
• Physical health addressed while being financially savy is possible.
• Pitfalls when assessing cryoablation or other technologies for treating prostate cancer
• Plans focusing on Wellness all too often forget mental health
• Plastic Surgery Discounts
• Preliminaries are Impressive??
• Price Transparency is Foreign to Most Health Care Providers
• Problem eating is not gender-limited and it is part and parcel of the "obesity epidemic"
• Promising Stem Cell Therapy?
• Proper Pharmacologic Treatment of ADHD reduces risk of substance abuse
• Provenge deserved FDA fate
• Pulsed Dye Vs Excimer Laser for Psoriasis
• Pulsed radiofrequency (PRF) in treating chronic back pain seems effective.
• Pulsed radiofrequency (PRF) in treating chronic back pain seems effective.
• Pulsed Radiofrequency treatment will be hard to prove.
• Putting nails into the coffin
• Quality Inititiatives are neccessary but will they last?
• Rebooting The Immune System-- Early Steps In A New Diabetes Treatment Direction
• Recent Trends Give Xyzal Blockbuster Potential
• Reimbursement keys adoption of new medical device technology
• remote monitoring will assist with tele-medicine in the field of arrhythmias
• Restless Leg Syndrome Commonly Presents to Psychiatry Clinics
• Restless Leg Syndrome: Diagnosis and Treatment Growing
• Retail clinics -- fighting back.
• Retail Clinics and other Nontraditional Primary Care Sites are Here to Stay and Will Play an Ever Increasing Role
• Retail clinics inevitable?
• Retail clinics will succeed only where access to Primary Care Physicians is limited
• Retail Clinics: A Disruptive Event, But a Boon to Patients
• Retail health care is good for patients....within limits
• Retail health clinics--both sides of the story
• REVERSIBLE ERROR: Merck Receives Non Approvable Letter from FDA
• Right target; Wrong outcome.
• Rosiglitazone meta-analysis without merit
• Safety a major concern
• Satraplatin not Vidaza and Thalidomide is the way of the future for Pharmion
• Save your money SNN
• School Nurtures Our Minds, and Must Guide Us in Nurturing our Bodies as Well
• Senate Bills Weigh in on Drug Importation, Drug Safety, Generics and FDA Changes
• Sentinel node biopsy already standard of care
• Shaky data is all government needs to go after the makers of Avandia.
• Shire (SHPGY) Builds An Empire That Will Be Difficult to Topple
• Shire's Broad ADHD Platform
• Shooting with no evidence
• Short course therapy wins again
• Short revision
• Side effect a major issue
• Siemens' breakthrough MRI-PET technology is a home run
• Simcor: Statin/Niacin is the Future
• Singulair in Exercise-induced asthma
• Slim chance for a big impact
• Software for Emergency Room Care
• SoloStar may become the new star in insulin administration
• Something new for Pandemic Flu
• SRV in non responders
• States are watering down AMP's impact on drug reimbursement
• Stem cells for diabetes
• Stenting dilemmas: Is it the Stent or the Patient?
• Still, it might provide only temporal improvement and is not solving the problem
• Study to boost sales of Advair
• S-U-C-E-S-S = Abbott Announces FDA Clearance And Launch Of New FreeStyle Lite™ Blood Glucose Monitoring System
• Supreme Court is More Political than Legal
• Technology Misused: Why Managed Care Has a Bad Name
• Telaprevir might be a valuable drug for hepatitis C treatment
• Telbivudine is a new option for patients with hepatitis
• Telemedicine could address the needs of psychiatry in which there is a distinct shortage of trained psychiatrists compared to those who need their services
• Thai Pharmaceutical market can expect growth
• The "Hawk" Strikes Again...
• The BEST treatment for asthma lies in the accurate identfication of its triggers!
• The brain is an electromagnetic organ so you might observe or alter both to facilitate response
• The Challenge of Internet Advertising
• The Device Playing Field in Psychiatry: rTMS, VNS, and DBS
• The Diet & Wellness Trend and Its Newest Technologies
• The effectiveness of subunit vaccines?
• The Eli Lilly (LLY) MEMOIR pen is a leap forward in diabetes care
• The EMEA and Vectibix
• THE END OF PARTIAL BIRTH ABORTION AND ABORTION in the USA
• The future of Avandia
• The future of fluoroscopy is bright indeed
• The good and the bad of Spyglass
• The Hammer Falls......
• The jury is still out
• The Marketing of Medicare Advantage Plans by Wellcare and other Health Plans
• The new formulation of clozapine will make administration easier but will be more expensive, but will it be used?
• The New Pen Saves Lantus
• The PBM wins
• The real value of PET scanning
• The Same Old Song...
• The sky's the limit
• The U.S. market likes Viagra--why not a stiff tongue for sleep apnea?
• The Use of Atypical Antipsychotics in Children and Adolescents
• The wrong solution for a vexing problem
• Therapy with PDT is worthless in the world of anti-VEGF agents
• There are only so many hours in a day--so if you spend a lot of time at the casino...
• Theres Nobody Home
• They Put the "Patient" in Patient Safety
• Thiazolidinedione + Incretins=Weight Loss + Improved Glycemic Control
• This drug has little advantage of existing drugs and will be difficult to get insurance approvals
• This Drug is No Sleeper
• Thrombopoietin Revisited.
• Timing is everything here.
• Title: Coca-Cola purchases a Health Drink Company – Energy Brands
• TLC Vision (TLCV) to sell Occulogix (OCCX) stake to Private Equity Firm.
• To become a blockbuster drug in oncology is not depending on the amount of the effective dosage
• Too much of a good thing?
• Too much too late??
• Toothpaste a mix of hype and good things for the mouth.
• Torisel versus Sutent
• Torisel's approval is NOT surprising; More indications to follow.
• TPI 287: Anew taxane that may be promising in brain gliomas
• TRA assessment
• TRA-SCH 530348 in preventing vascular thrombotic events
• Treating Pain: What’s on the Horizon?
• Treatment of ADHD: stuck between a rock and a hard place
• Treatment Planning using Digital Fluoroscopy
• Tyrosine kinases continue to offer clues to cancer genetics and potential treatments
• Tysabri in MS
• unifromity of services
• Urgent Need for Better Treatement for Excessive Sleepiness
• Urgent need for clinical trials in ALS
• Use according to guidelines
• Use of Fluroscopy
• useful addition as topical antibiotic
• Useful if taken properly
• Vaccines for pancreatic cancer: Will Primovax work for unresectable tumors??
• Vanda's VSF-173 for Excessive Sleepiness
• VEGF Trap continues to show promising data for wet AMD Treatment
• VEGF Trap vs. Lucentis
• Vertigraft VG2 is not likely to make an appreciable impact on DePuy Spine performance
• Virtually none
• Visualization is Key to Stent Placement & Deployment
• Vitamin supplementation is really all we have currently in the treatment of dry AMD. AMD is becoming a crisis of epidemic propotions, new therapies are needed.
• Vitamins and Prostate Cancer - too much of a good thing?
• Wellpoint, HMOs and Medical Cost Ratios
• When you claim you are giving a certain dose of a medication you should deliver
• Where there is HOPE-
• Why not study it for osteoporosis?
• Why not?
• Why should I prescribe this drug?
• Why the US lags the developed world in electronic medical records
• Will AMO's contact lens solution problem be the same as Bausch and Lomb's?
• Will it make our food supply safer?
• Will it work and what are the downsides?
• Will the extended release formulation mitigate abuse potential of quetiapine
• Will they bite? What about the other fish??
• Will vaccine therapy ever affect cancer outcome
• Will Vegf Trap (Regeron; RGN) beat out Lucentis (Genentech; DNA)?
• Will zanolimumab (HuMax-CD4) add to CTCL ?
• Win-win
• World Wide Market!
• wyeth
• Wyeth's Lybrel could it be the new Norplant or Dalcon Shield? - Class actions to follow?
• Yes, but will not curb TB in the 3rd World
• You can dress it up but you cant take it out
• Young whipper snappers should not belittle the importance of stroke or recurrent MI
• Zyrtec without the side effects